CryoCath makes appointment
This article was originally published in Scrip
CryoCath Technologies (Canada), a medical technology company focused on cryotherapy products to treat cardiac arrhythmias, has appointed Frank Vandeputte vice-president, Europe. Based in CryoCath's new European headquarters in Leiden, the Netherlands, Mr Vandeputte will be responsible for leading the European business operation. He joins the company with more than 20 years' experience in the medical device industry. Most recently, he served as area vice-president Benelux and Nordic for the Sorin Group, based in Brussels.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.